Attend the FierceBiotech Drug Development Forum
The leading executive-level forum for biotech strategy & networking | Oct 28-29 | Boston
Celgene of Summit, New Jersey, says that the FDA has accepted its NDA for Revlimid. Release
Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.
The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.
The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.